Clozapine-induced maculopathy

Mack, Heather G; Symons, RC Andrew

doi:10.5694/mja17.00384

Topics

We thank Tong and colleagues1 for their report on a patient with schizophrenia and clozapine-induced maculopathy, and for highlighting this under-recognised condition.

1 University of Melbourne, Melbourne, VIC
2 Melbourne Health, Melbourne, VIC

Correspondence: hmack@eyesurgery.com.au

Competing interests:

No relevant disclosures.

1. Tong JY, Pai A, Heydon P, Young SH. Clozapine-induced maculopathy. Med J Aust 2017; 206: 246. <MJA full text>
2. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010; 24: 501-526.
3. Faure C, Audo I, Zeitz C, Letessier JB, Robert MP. Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features. Doc Ophthalmol 2015; 131: 35-41.
4. Lee MS, Fern AI. Fluphenazine and its toxic maculopathy. Ophthalmic Res 2004; 36: 237-239.
5. Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. Med J Aust 2009; 190: 210-211. <MJA full text>
6. Clemens CR, Alten F, Loos D, et al. Poppers maculopathy or retinopathy? Eye 2015; 29: 148-149.
7. Ascaso FJ, Rodriguez-Jimenez R, Cabezón L, et al. Retinal nerve fiber layer and macular thickness in patients with schizophrenia: Influence of recent illness episodes. Psychiatry Res 2015; 229: 230-236.

Online responses are no longer available. Please refer to our instructions for authors page for more information.